The Perfect Enemy | Moderna says U.S. on the hook in COVID-19 vaccine patent case - Reuters
May 26, 2022

Moderna says U.S. on the hook in COVID-19 vaccine patent case – Reuters

Moderna says U.S. on the hook in COVID-19 vaccine patent case  ReutersView Full Coverage on Google News

Read Time:2 Minute

A vial labelled “Moderna COVID-19 Vaccine” is seen in this illustration taken January 16, 2022. REUTERS/Dado Ruvic

Register now for FREE unlimited access to Reuters.com

  • Moderna says it’s immune from claims as a government supplier
  • Denies infringing Arbutus, Genevant patents

(Reuters) – Facing claims that its COVID-19 vaccine violates the patent rights of two biopharma companies, Moderna Inc told a Delaware federal court on Friday that the companies should have sued the U.S. government instead.

Moderna said it is shielded from the lawsuit brought by Arbutus Biopharma Corp and Genevant Sciences GmbH, thanks to its agreement to supply the vaccine to the federal government. It cited a federal law that was previously used to keep patent claims from interfering with the supply of war materials during World War I.

“Short of war, it is difficult to conceive of a situation more within the heart” of the statute “than the COVID-19 crisis,” Moderna said in a filing asking the court to dismiss the lawsuit.

Register now for FREE unlimited access to Reuters.com

It said its vaccine did not infringe the companies’ patents, “but that dispute is for later.”

A spokesperson for Genevant said Monday that Moderna was “trying to shift responsibility for its patent infringement to the U.S. taxpayer” instead of responding to the claims.

The U.S. Food and Drug Administration on Monday declined to comment on Moderna’s filing.

Moderna said in a statement that Arbutus and Genevant had “sued the wrong party in the wrong court,” and denied that its technology infringed.

Warminster Township, Pennsylvania-based Arbutus and Genevant, a joint venture launched by Arbutus and Roivant Sciences Ltd, sued Moderna in February. They said the lipid nanoparticles (LNPs) Moderna’s vaccines use to transport genetic material into human cells infringe patents on LNP technology that Arbutus owns and licenses to Genevant.

LNPs have been at the center of multiple patent lawsuits involving Moderna and Pfizer’s COVID-19 vaccines.

Arbutus and Genevant asked for royalties on Moderna’s multi-billion dollar sales of the vaccine. But Moderna said Friday that their only recourse is to sue the federal government in the U.S. Court of Federal Claims because Moderna supplied the shots for the government’s nationwide vaccination effort.

The case is Arbutus Biopharma Corp v. Moderna Inc, U.S. District Court for the District of Delaware, No. 1:22-cv-00252.

For Moderna: Patricia Carson and James Hurst of Kirkland & Ellis, Jack Blumenfeld of Morris Nichols Arsht & Tunnell

For Arbutus and Genevant: David Berl of Williams & Connolly, Daralyn Durie of Durie Tangri, John Shaw of Shaw Keller

(NOTE: This story has been updated with a response from the U.S. Food and Drug Administration.)

Read more:

Arbutus files patent infringement lawsuit against Moderna related to COVID shot

COVID-19 patent challenges mount as Moderna faces new vaccine lawsuit

Canadian Pfizer partner sues to head off patent lawsuit over COVID-19 vaccine

Register now for FREE unlimited access to Reuters.com

Our Standards: The Thomson Reuters Trust Principles.

Blake Brittain

Thomson Reuters

Blake Brittain reports on intellectual property law, including patents, trademarks, copyrights and trade secrets. Reach him at blake.brittain@thomsonreuters.com